Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 13;4(1):e000776.
doi: 10.1136/bmjpo-2020-000776. eCollection 2020.

Cost of nitric oxide therapy in neonates

Emily Hoyle  1 , Hannah Spierson  1 , David Cordon  1 , Joanne Brady  1 , Nimish V Subhedar
Affiliations

Cost of nitric oxide therapy in neonates

Emily Hoyle et al. BMJ Paediatr Open. .

Abstract

A retrospective observational cohort study was performed to review the cost of inhaled nitric oxide (iNO) therapy in a UK neonatal intensive care setting over a 4-year period. 188 neonates with a median (IQR) gestational age and birth weight of 27 (24-37) weeks and 980 (695-2812) g, respectively, were treated with iNO. The median (IQR) duration of iNO therapy was 60 (22-129) hours. The mean cost of iNO therapy was approximately £820 per baby treated equivalent to £8.50 per hour of therapy. Alternative pricing models suggested a calculated cost of iNO therapy of between approximately £950 and £1350 per baby.

Keywords: data collection; neonatology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Until December 2019, NVS chaired the European Inhaled Nitric Oxide Registry which was commercially funded by a variety of suppliers of inhaled nitric oxide, none of which had a role in this study.

References

    1. Sokol GM, Konduri GG, Van Meurs KP. Inhaled nitric oxide therapy for pulmonary disorders of the term and preterm infant. Semin Perinatol 2016;40:356–69. 10.1053/j.semperi.2016.05.007 - DOI - PMC - PubMed
    1. European medicines Agency, INOmax, summary of product characteristics. Available: https://www.ema.europa.eu/en/medicines/human/EPAR/inomax
    1. Konduri GG, Menzin J, Frean M, et al. . Inhaled nitric oxide in term/late preterm neonates with hypoxic respiratory failure: estimating the financial impact of earlier use. J Med Econ 2015;18:612–8. 10.3111/13696998.2015.1038270 - DOI - PubMed
    1. Subhedar NV, Jauhari P, Natarajan R. Cost of inhaled nitric oxide therapy in neonates. Lancet 2002;359:1781–2. 10.1016/S0140-6736(02)08632-4 - DOI - PubMed
    1. Brown S, Hurren J, Sartori H. Poractant alfa versus Beractant for neonatal respiratory distress syndrome: a retrospective cost analysis. J Pediatr Pharmacol Ther 2018;23:367–71. 10.5863/1551-6776-23.5.367 - DOI - PMC - PubMed

LinkOut - more resources